• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Robbins Jim B

    1/6/22 4:03:01 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VIVE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Robbins Jim B

    (Last) (First) (Middle)
    C/O VIVEVE MEDICAL, INC.
    345 INVERNESS DRIVE S., BLDG B, STE 250

    (Street)
    ENGLEWOOD CO 80112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    VIVEVE MEDICAL, INC. [ VIVE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    SVP, Finance & Administration
    3. Date of Earliest Transaction (Month/Day/Year)
    01/04/2022
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Incentive Stock Option (Right to Purchase) $1.26 01/04/2022 A 42,000 (1) 01/03/2032 Common Stock 42,000 $0 42,000 D
    Explanation of Responses:
    1. The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan, as amended (the "2013 Plan") and received 42,000 incentive stock options on January 4, 2022 (the "Grant Date"). The incentive stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date.
    /s/ Jim Robbins 01/06/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VIVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VIVE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VIVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Basta Steven L

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:04:01 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Durbin Scott

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:03:31 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Jorn Debora

    4 - VIVEVE MEDICAL, INC. (0000879682) (Issuer)

    1/5/23 4:03:15 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

    Study's primary efficacy endpoint was not achieved at 12 months post-treatmentCompany has implemented a reduction in forceCompany will seek strategic alternatives and will be delisted from Nasdaq ENGLEWOOD, CO / ACCESSWIRE / January 17, 2023 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced topline result from the U.S. Pivotal PURSUIT clinical trial. PURSUIT was a multicenter, randomized, double-blinded, sham-controlled U.S. study to evaluate the safety and efficacy of the Viveve treatment for SUI in women. The results were obtained by the company on Friday evening, Janu

    1/17/23 6:30:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

    Topline results of the 12-month primary efficacy endpoint anticipated in January 2023Positive results may support a de novo marketing application for a new U.S. indication for treatment of stress urinary incontinence in womenENGLEWOOD, CO / ACCESSWIRE / December 15, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and treatment of female stress urinary incontinence, today announced the completion of final 12-month post-treatment follow-up visits in its landmark U.S. PURSUIT clinical trial for the treatment of stress urinary incontinence (SUI) in women. A total of 415 patients were enrolled in the trial, and 342 patients completed 12-month foll

    12/15/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

    Patent further strengthens Viveve's novel dual-energy technology intellectual property portfolio as company plans for completion of pivotal PURSUIT clinical trialENGLEWOOD, CO / ACCESSWIRE / December 1, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve's treatment to address SUI in women. The issuance of the new patent strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the e

    12/1/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Viveve Medical

    Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy

    1/30/21 7:59:20 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Alliance Global Partners initiated coverage on Viveve Medical with a new price target

    Alliance Global Partners initiated coverage of Viveve Medical with a rating of Buy and set a new price target of $10.75

    1/29/21 7:09:51 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    SEC Filings

    View All

    SEC Form 15-12G filed by Viveve Medical Inc.

    15-12G - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    2/6/23 4:02:17 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Viveve Medical Inc.

    EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    1/31/23 12:15:28 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form EFFECT filed by Viveve Medical Inc.

    EFFECT - VIVEVE MEDICAL, INC. (0000879682) (Filer)

    1/31/23 12:15:10 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Financials

    Live finance-specific insights

    View All

    Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo

    11/10/22 4:02:00 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

    ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we

    10/27/22 8:28:00 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Viveve Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We

    8/11/22 4:01:00 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VIVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Viveve Medical Inc. (Amendment)

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    2/4/22 4:17:42 PM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Viveve Medical Inc. (Amendment)

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    1/18/22 11:21:09 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - VIVEVE MEDICAL, INC. (0000879682) (Subject)

    2/16/21 11:21:31 AM ET
    $VIVE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care